In light of recent studies that have shown a detrimental effect of some MS disease-modifying drugs in NMO [65]–[73], the possibility of using OCT for a more accurate diagnosis of NMO and for a correct differential diagnosis versus MS would be desirable, especially in AQP4 antibody negative patients. This evidence concerns the gene AQP4 and myeloid sarcoma.